Telaprevir for chronic HCV infection

New England Journal of Medicine

Volumn 361, Issue 5, 2009, Pages 534-

  Kao, Jia Horng ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ADD ON THERAPY; ANTIVIRAL THERAPY; ASIAN; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; EUROPEAN AMERICAN; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; PRIORITY JOURNAL; VIROLOGY;

ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 68049142597     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Hoofnagle JH. A step forward in therapy for hepatitis C. N Engl J Med 2009;360:1899-1901
2. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008;47:1884-1893 (Pubitemid 351945556)
3. Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008;47:1260-1269
4. Hsu CS, Liu CJ, Lai MY, Chen PJ, Kao JH, Chen DS. Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. Intervirology 2007;50:310-315 (Pubitemid 47091849)